Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Microorganisms · 2026
Review
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Natasia HoshibaResearch & Development Department, Ina Food Industry, Co., Ltd., Ina 399-4498, Nagano, Japan.ORCID 0009-0002-1695-1719
Tadashi FujiiDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Rina YagasakiResearch & Development Department, Ina Food Industry, Co., Ltd., Ina 399-4498, Nagano, Japan.
Toshiyuki OchiResearch & Development Department, Ina Food Industry, Co., Ltd., Ina 399-4498, Nagano, Japan.
Katsuhiro ShibaResearch & Development Department, Ina Food Industry, Co., Ltd., Ina 399-4498, Nagano, Japan.
Hideaki TakahashiDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0009-0003-9384-6952
Kohei FunasakaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Eizaburo OnoDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Yoshiki HirookaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0001-9639-7425
Takumi TochioDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Koji KarasawaResearch & Development Department, Ina Food Industry, Co., Ltd., Ina 399-4498, Nagano, Japan.ORCID 0000-0001-9746-364X
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
3,6-anhydro-L-galactose cycloisomeraseagaro-oligosaccharidesBacteroides uniformisgut microbiotahealthy Japanese adultsopen-label pilot studyprebioticRuminococcus gnavus
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Agaro-Oligosaccharide Supplementation Alters the Gut Microbiota, Revealing Potential Agaro-Oligosaccharide-Utilizing Taxa in Healthy Japanese Adults. · full record | OpenQuestion